|
|
 | | | |
- close
- close
- close
- close
Synta Pharmaceuticals (SNTA) |
TheStreet.com
Jun 7
Comment
span.style4 {font-size: 10px; font-weight: bold; }
span.style5 {font-size: 10px}
By Jonathan Moreland, founder of Insider Insights and author of Profit From Legal Insider Trading.
NEW YORK (TheStreet) -- It is a victory for...
Benzinga
Jun 6
Comment
VeriFone Systems (NYSE: PAY) plunged 18.75% to $17.82 after the the company reported downbeat second-quarter results and issued a weak forecast.
Synta Pharmaceuticals (NASDAQ: SNTA) dropped 11.50% to $4.09 amid shorter survival benefits...
Benzinga
Jun 4
Comment
On the heels of a 34 percent plunge in shares of Synta Pharmaceuticals (NASDAQ: SNTA) on Monday amid shorter survival benefits from GALAXY-1 Phase 2b/3 trial of ganetespib, Roth Capital's Joseph Pantginis is recommending investors buy the dip in...
Benzinga
Jun 3
Comment
Synta Pharmaceuticals (NASDAQ: SNTA) is down 32.32% to $4.99 after Synta reported positive overall survival results from GALAXY-1 Phase 2b/3 trial of Ganetespib in second-line non-small cell lung cancer.
Infinity Pharmaceuticals (NASDAQ: INFI)...
StreetInsider.com
Jun 3
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Synta+Pharma+%28SNTA%29+Issues+Encouraging+Update+from+GALAXY-1%3B+OS%2C+PFS+Improve+w+Ganetespib/8384050.html for the full story.
TheStreet.com
Jun 3
Comment
CHICAGO (TheStreet) -- The efficacy of Synta Pharmaceuticals' lung cancer drug ganetespib is weakening over time, which should raise even more concerns about the ongoing phase III clinical trial.
Snyta shares are down 17% to $6.15 in early...
TheStreet.com
May 14
Comment
LEXINGTON, Calif (TheStreet) -- Biotech run-up traders should be looking at a potentially valuable clinical trial catalyst with Synta Pharmaceuticals .
Synta is scheduled to present updated results from phase II (GALAXY-1) portion of its...
TheStreet.com
May 10
Comment
BOSTON (TheStreet) -- This week's Biotech Stock Mailbag is open for business.
@adamfeuerstein SNTA getting hit hard, do you suspect SNTA to respond with a PR/Statement of some sort?Bit hard to ignore, I would think?— Bill H. (@bheafey) May 8,...
StreetInsider.com
May 7
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Synta+Pharma+%28SNTA%29+Sell-Off+Related+to+R%26D+Pres.+Resignation%2C+Could+Be+Buying+Opp/8312309.html for the full story.
StreetInsider.com
Apr 30
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Synta+Pharmaceuticals%2C+Inc.+%28SNTA%29+Posts+Q1+Loss+of+30cShare/8287877.html for the full story.
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
